1 |
TEKCHAM D S, CHEN D, LIU Y, et al. F-box proteins and cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects[J]. Theranostics, 2020, 10(9): 4150-4167.
|
2 |
SMALDONE S, LAUB F, ELSE C, et al. Identification of MoKA, a novel F-box protein that modulates Krüppel-like transcription factor 7 activity[J]. Mol Cell Biol, 2004, 24(3): 1058-1069.
|
3 |
SMALDONE S, RAMIREZ F. Multiple pathways regulate intracellular shuttling of MoKA, a co-activator of transcription factor KLF7[J]. Nucleic Acids Res, 2006, 34(18): 5060-5068.
|
4 |
MENG X B, LIU X W, GUO X D, et al. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells[J]. Nature, 2018, 564(7734): 130-135.
|
5 |
CHAR D H. Ocular melanoma[J]. Surg Clin N Am, 2003, 83(2): 253-274.
|
6 |
KIRCHBERGER M C, MOREIRA A, ERDMANN M, et al. Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients[J]. Oncotarget, 2018, 9(48): 28903-28909.
|
7 |
JAGER M J, SHIELDS C L, CEBULLA C M, et al. Uveal melanoma[J]. Nat Rev Dis Primers, 2020, 6(1): 24.
|
8 |
GRIMES J M, SHAH N V, SAMIE F H, et al. Conjunctival melanoma: current treatments and future options[J]. Am J Clin Dermatol, 2020, 21(3): 371-381.
|
9 |
LI X, ZHAI J, SHEN Y K, et al. Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells[J]. Cancer Immunol Immunother, 2022, 71(12): 3057-3070.
|
10 |
WANG Z, LIU P, INUZUKA H, et al. Roles of F-box proteins in cancer[J]. Nat Rev Cancer, 2014, 14(4): 233-247.
|
11 |
GEORGES A, COYAUD E, MARCON E, et al. USP7 regulates cytokinesis through FBXO38 and KIF20B[J]. Sci Rep, 2019, 9(1): 2724.
|
12 |
DIBUS N, KORINEK V, CERMAK L. FBXO38 ubiquitin ligase controls centromere integrity via ZXDA/B stability[J]. Front Cell Dev Biol, 2022, 10: 929288.
|
13 |
DIBUS N, ZOBALOVA E, MONLEON M A M, et al. FBXO38 ubiquitin ligase controls sertoli cell maturation[J]. Front Cell Dev Biol, 2022, 10: 914053.
|
14 |
AKÇIMEN F, VURAL A, DURMUŞ H, et al. A novel homozygous FBXO38 variant causes an early-onset distal hereditary motor neuronopathy type IID[J]. J Hum Genet, 2019, 64(11): 1141-1144.
|
15 |
CISAROVA K, FOLCHER M, EL ZAOUI I, et al. Genomic and transcriptomic landscape of conjunctival melanoma[J]. PLoS Genet, 2020, 16(12): e1009201.
|
16 |
VIGNA E, NALDINI L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy[J]. J Gene Med, 2000, 2(5): 308-316.
|
17 |
LIANG J Y, SLINGERLAND J M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression[J]. Cell Cycle, 2003, 2(4): 339-345.
|
18 |
WESTIN J R. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma[J]. Clin Lymphoma Myeloma Leuk, 2014, 14(5): 335-342.
|
19 |
DONG Y, RICHARDS J A, GUPTA R, et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response[J]. Oncogene, 2014, 33(38): 4632-4642.
|
20 |
WANG R, TAHIRI H, YANG C, et al. MiR-181a-5p inhibits uveal melanoma development by targeting GNAQ and AKT3[J]. Am J Cancer Res, 2023, 13(1): 293-306.
|
21 |
NUNNERY S E, MAYER I A. Management of toxicity to isoform α-specific PI3K inhibitors[J]. Ann Oncol, 2019, 30: x21-x26.
|
22 |
HE Y, SUN M M, ZHANG G G, et al. Targeting PI3K/Akt signal transduction for cancer therapy[J]. Signal Transduct Target Ther, 2021, 6(1): 425.
|
23 |
YIP P Y. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer[J]. Transl Lung Cancer Res, 2015, 4(2): 165-176.
|
24 |
ACCILI D, ARDEN K C. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation[J]. Cell, 2004, 117(4): 421-426.
|
25 |
VECINO R, BURGUETE M C, JOVER-MENGUAL T, et al. The MDM2-p53 pathway is involved in preconditioning-induced neuronal tolerance to ischemia[J]. Sci Rep, 2018, 8(1): 1610.
|
26 |
MAYO L D, DONNER D B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus[J]. Proc Natl Acad Sci USA, 2001, 98(20): 11598-11603.
|
27 |
CANTLEY L C. The phosphoinositide 3-kinase pathway[J]. Science, 2002, 296(5573): 1655-1657.
|
28 |
KATSO R, OKKENHAUG K, AHMADI K, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer[J]. Annu Rev Cell Dev Biol, 2001, 17: 615-675.
|